Back to Search
Start Over
Blood Targets of Adjuvant Drugs Against COVID19
- Source :
- Journal of Blood Medicine. 11:237-241
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-known drugs such as anticoagulants, antihypertensives, antiserotoninergics and immunomodulants. We here report a basic list of these drugs that include bioflavonoids, heparinoids, ACE inhibitors, angiotensin receptor blockers, antiserotoninergics, and monoclonal antibodies against cytokines that may interact with the viral cycle.
- Subjects :
- 2019-20 coronavirus outbreak
business.industry
medicine.drug_class
medicine.medical_treatment
Interleukin
Hematology
Heparin
030204 cardiovascular system & hematology
Pharmacology
Monoclonal antibody
03 medical and health sciences
0302 clinical medicine
Viral protease
030220 oncology & carcinogenesis
medicine
Angiotensin Receptor Blockers
business
Heparinoids
Adjuvant
medicine.drug
Subjects
Details
- ISSN :
- 11792736
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Journal of Blood Medicine
- Accession number :
- edsair.doi...........14148c3d2f5d809004d02a83c9d5d6c9